Floatz logo

Vosaroxin

Leukemia

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB

View all 50 →

Same molecule, other indications

Vosaroxin is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
61 / 100
View asset →
acute myeloid leukemia with multilineage dysplasiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →